SCYNEXIS Inc
SCYNEXIS Inc (SCYX) is a small-cap biotechnology company focused on developing novel antifungal therapies. With a market capitalisation of about $32.7 million, it is a relatively small, specialised issuer where clinical progress and regulatory milestones tend to drive valuation. Investors should note the typical biotech risk profile: research and development outcomes, trial results and approvals can materially affect the share price, while revenues may be limited or intermittent. SCYNEXIS’s work centres on antifungal medicines addressing unmet needs; success would depend on clinical efficacy, safety, reimbursement and commercial execution. The company can appeal to investors seeking exposure to specialty infectious-disease science, but it is more suitable for those comfortable with higher volatility, long development timelines and binary news events. This summary provides general educational information only and is not personal financial advice — consider your objectives and seek professional guidance before investing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying SCYNEXIS's stock with a target price of $6.67, indicating strong growth potential.
Financial Health
SCYNEXIS Inc is earning revenue and managing costs well, but overall performance is moderate.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SCYX
Targeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: August 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline-Driven Value
Company value is heavily influenced by clinical and regulatory milestones, which can create rapid share movement — though outcomes are uncertain.
Specialist Therapeutics
Focus on antifungal treatments targets an underserved area of infectious disease, but commercial uptake and reimbursement are not guaranteed.
Catalysts To Watch
Key catalysts include trial results, approvals and partnerships; monitor cash runway and financing as they affect execution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
